Alicia K. Morgans, MD, MPH, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

An in-depth discussion regarding experience treating nonmetastatic castration-resistant prostate cancer (CRPC) with apalutamide, enzalutamide, and darolutamide, and factors that impact treatment selection.

An overview of drug approvals for nonmetastatic castration-resistant prostate cancer (CRPC), and discussion regarding the potential utility of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) to guide treatment decisions.

Implications of treating patients with metastatic castration-sensitive prostate cancer with relugolix, an oral GnRH antagonist.

Recommendations for integrating treatment advances in metastatic castration-sensitive prostate cancer into everyday practice.

Potential implications for treating metastatic castration-sensitive prostate cancer with triple therapy based on recently reported data.

The rationale for treating metastatic castration-sensitive prostate cancer with androgen deprivation therapy as monotherapy as the field advances with newer combination approaches.

Treatment Advances in mCSPC

A discussion regarding use of the PSMA-targeted 18F-DCFPyL PET/CT to assess patients with suspected recurrence of prostate cancer based on data revealed by the CONDOR trial.

An interpretation of the OSPREY study of 18F-DCFPyL injection in patients with high-risk prostate cancer and implications of its use.

A discussion regarding the use of PSMA PET imaging to detect phenotypic biomarkers that may simplify approaches to precision medicine in advanced prostate cancer.

Dr Scott T. Tagawa comments on the pros and cons of liquid and tissue biopsies used to assess patients with advanced prostate cancer.

A panel of physicians who work in the field of genitourinary oncology comment on the evolving role of precision medicine in advanced prostate cancer.